PM
COGT icon

Prosight Management’s Cogent Biosciences COGT Stock Holding History

Prosight Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-410,830
Closed -$4.44M – 37
2024
Q3 		$4.44M Sell
410,830
-89,170
-18% -$868K 1.09% 26
2024
Q2 		$4.21M Sell
500,000
-55,500
-10% -$421K 1.26% 25
2024
Q1 		$3.73M Buy
+555,500
New +$3.43M 1.04% 27

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Prosight Management's COGT Position: Q4 2024 in Review

Prosight Management sold out of Cogent Biosciences (COGT) in Q4 2024, closing a stake of 410,830 shares — an estimated $4.44M sold.

Prosight Management first reported a position in COGT in Q1 2024 and held it in 3 quarters. The position peaked at $4.44M in Q3 2024. 176 funds tracked by Wall St. Rank hold COGT as of Q4 2024.

  • Prosight Management reported no remaining Cogent Biosciences position as of Q4 2024 after selling out during the quarter.
  • Prosight Management sold 410,830 Cogent Biosciences shares in Q4 2024, an estimated $4.44M.
  • Prosight Management first reported a position in Cogent Biosciences in Q1 2024 and held it in 3 quarters.
  • Prosight Management's Cogent Biosciences position peaked at $4.44M in Q3 2024.
  • 176 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2024.

Based on Prosight Management's 13F filing for Q4 2024, filed 14 Feb 2025.